Buffered-Urine Testing Did Not Validate Every Untreated Specimen for a Cannabis Chip
The microfluidic assay’s pH and specific-gravity checks were performed within a defined preparation workflow. They do not establish that any untreated urine specimen can be loaded without regard to dilution or matrix effects.
Preparation was part of the method
The investigators mixed urine with a specified sample buffer before loading the microchannels. The buffer was intended to reduce matrix-related variability. Their methods report no changes in positive and negative classifications across the tested variations in pH and specific gravity.
The null classification result has boundaries
Maintained classifications within the tested range are useful evidence of robustness. They do not show that every possible urine condition is harmless or that the unbuffered method would perform identically. Nor does unchanged positive/negative classification establish that the underlying fluorescence values were identical.
A result depends on following the validated preparation
For a case review, the relevant question is whether the specimen was prepared as the evaluated method required. Substituting another buffer, changing proportions or omitting preparation creates a different workflow whose performance needs support. The experiment also did not validate a generic rule that a negative cannabinoid result means a specimen is physiologically normal or free of interference. The matrix checks concern analytical classification, not the person’s impairment. Preserving the preparation details avoids treating a useful robustness result as unlimited immunity to specimen variability.
Related analysis: what the urine platform measured.
Research cited
Ko and colleagues. On-Site Microfluidic Assay for the Detection of Multiple Drugs in Urine. ACS Omega (2026). DOI: 10.1021/acsomega.5c11027.



